APD791, 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy) phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: Pharmacological profile, pharmacokinetics, platelet activity and vascular biology

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 96-103

  Adams, John W ^a   Ramirez, Juan ^a   Shi, Yunqing ^a   Thomsen, William ^a   Frazer, John ^a   Morgan, Michael ^a   Edwards, Jeffrey E ^a   Chen, Weichao ^a   Teegarden, Bradley R ^a   Xiong, Yifeng ^a   Al Shamma, Hussien ^a   Behan, Dominic P ^a   Connolly, Daniel T ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXY N [3 [1 METHYL 1H PYRAZOL 5 YL] 4 (2 MORPHOLINOETHOXY)PHENYL]BENZAMIDE; APD 791; DRUG METABOLITE; G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; INVERSE AGONISM; MAXIMUM PLASMA CONCENTRATION; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANIMALS; AORTA; BENZAMIDES; BLOOD PLATELETS; CELL LINE; CROSS-OVER STUDIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAPLORHINI; HUMANS; MALE; MORPHOLINES; MUSCLE, SMOOTH, VASCULAR; PLATELET ACTIVATION; PYRAZOLES; RABBITS; RATS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS; SPECIES SPECIFICITY;

EID: 70349338807     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.153189     Document Type: Article

References (27)

1. Adams JW, Ramirez J, Ortuno D, Shi Y, Thomsen W, Richman JG, Morgan M, Dosa P, Teegarden BR, Al-Shamma H, et al. (2008) Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist. Eur J Pharmacol 586:234-243.
2. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, and Willerson JT (1986) Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 73:572-578. (Pubitemid 16133036)
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Cooke GE and Goldschmidt-Clermont PJ (2006) The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opin Drug Saf 5:815-826. (Pubitemid 44669496)
5. De Clerck FF and Herman AG (1983) 5-Hydroxytryptamine and platelet aggregation. Fed Proc 42:228-232.
6. De Clerck FF and Janssen PA (1990) Amplification mechanisms in platelet activation and arterial thrombosis. J Hypertens Suppl 8:S87-S93.
7. Drummond AH and Gordon JL (1974) Proceedings: platelet release reaction induced by 5-hydroxytryptamine. J Physiol 240:39P-40P.
8. Frishman WH and Grewall P (2000) Serotonin and the heart. Ann Med 32:195-209.
9. Fujita M, Mizuno K, Ho M, Tsukahara R, Miyamoto A, Miki O, Ishii K, and Miwa K (2003) Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J 145:E16.
10. Grotewiel MS and Sanders-Bush E (1999) Differences in agonist-independent activity of 5-Ht2A and 5-HT2c receptors revealed by heterologous expression. Naunyn Schmiedebergs Arch Pharmacol 359:21-27.
11. Herbert JM, Bernat A, Barthelemy G, Dol F, and Rinaldi M (1993) Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist. Thromb Haemost 69:262-267. (Pubitemid 23069005)
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
13. Israilova M, Suzuki F, Tanaka T, Nagatomo T, Taniguchi T, and Muramatsu I (2002) Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology 65:69-73. (Pubitemid 34298008)
14. Kaumann AJ and Levy FO (2006) 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111:674-706. (Pubitemid 44118434)
15. Kihara H, Koganei H, Hirose K, Yamamoto H, and Yoshimoto R (2001) Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur J Pharmacol 433:157-162. (Pubitemid 34045174)
16. Kroeze WK, Kristiansen K, and Roth BL (2002) Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2:507-528.
17. Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R, Eto T, and Asada Y (2006) Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost 4:247-255.
18. Ogawa T, Sugidachi A, Tanaka N, Fujimoto K, and Asai F (2002) Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444. Eur J Pharmacol 457:107-114. (Pubitemid 35447652)
19. Pawlak D, Adamkiewicz M, Malyszko J, Takada A, Mysliwiec M, and Buczko W (1998) Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats. J Cardiovasc Pharmacol 32:266-273. (Pubitemid 28350647)
20. Prevention of Atherosclerotic Complications with Ketanserin Trial Group (1989) Prevention of atherosclerotic complications: controlled trial of ketanserin. Br Med J 298:424-430. (Pubitemid 19056461)
21. Przyklenk K, Linden MD, Frelinger AL III, Teegarden B, Adams J, and Michelson AD (2007) Abstract 1034: Targeted inhibition of the serotonin 5-HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. Circulation 116:II-206.
22. Rashid M, Manivet P, Nishio H, Pratuangdejkul J, Rajab M, Ishiguro M, Launay JM, and Nagatomo T (2003) Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci 73:193-207.
23. Schins A, Honig A, Crijns H, Baur L, and Hamulyák K (2003) Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as missing link?. Psychosom Med 65:729-737. (Pubitemid 37163376)
24. 2A serotonin receptor useful for the treatment of disorders related thereto. PCT US2005/041726 (World patent WO 2006055734). 2006 May 26.
25. Van Nueten JM, Janssen PA, Van Beek J, Xhonneux R, Verbeuren TJ, and Vanhoutte PM (1981) Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218:217-230. (Pubitemid 11033743)
26. Vikenes K, Farstad M, and Nordrehaug JE (1999) Serotonin is associated with coronary artery disease and cardiac events. Circulation 100:483-489. (Pubitemid 29360156)
27. Yang LH, Callas D, Herbert JM, and Fareed J (1996) Modulation of platelet function and vascular smooth muscle contractile actions by a novel, selective, highly potent 5-HT2 antagonist (SR46349). Thromb Res 81:555-567. (Pubitemid 26101335)